The Experts below are selected from a list of 12999 Experts worldwide ranked by ideXlab platform
Ichiro Kusumi - One of the best experts on this subject based on the ideXlab platform.
-
combined treatment with subchronic lithium and acute intracerebral Mirtazapine microinjection into the median raphe nucleus exerted an anxiolytic like effect synergistically
European Journal of Pharmacology, 2016Co-Authors: Yan An, Yuji Kitaichi, Shin Nakagawa, Takeshi Inoue, Chong Chen, Ce Wang, Ichiro KusumiAbstract:Abstract Although preclinical and clinical studies have established the efficacy of lithium augmentation of antidepressant drugs, the mechanism of action of lithium augmentation is not fully understood. Our previous study reported that subchronic lithium treatment enhanced the anxiolytic-like effect of systemic Mirtazapine. In the present study, we examined the effect of subchronic lithium in combination with acute local intracerebral injection of Mirtazapine on fear-related behaviors in a contextual fear conditioning test in rats to clarify the target brain region of lithium augmentation of Mirtazapine. After conditioning by footshock, diet (food pellets) containing Li 2 CO 3 at a concentration of 0.2% was administered for 7 days. Ten min before testing and 7 days after conditioning, Mirtazapine (3 μg/site) in a volume of 0.5 µl was acutely injected into the median raphe nucleus (MRN), hippocampus or amygdala. The combination of subchronic lithium and acute Mirtazapine microinjection into the MRN but not the hippocampus or the amygdala reduced fear expression synergistically. These results suggest that intra-MRN Mirtazapine treatment with subchronic lithium exerts the anxiolytic-like effect through the facilitation of the MRN-5HT pathway.
-
Subchronic lithium treatment increases the anxiolytic-like effect of Mirtazapine on the expression of contextual conditioned fear
European journal of pharmacology, 2014Co-Authors: Takeshi Inoue, Yuji Kitaichi, Shin Nakagawa, Ning Song, Chong Chen, Ce Wang, Ichiro KusumiAbstract:Lithium not only has a mood-stabilizing effect but also the augmentation effect of an antidepressant, the mechanism of which remains unclear. Although lithium may augment the effect of Mirtazapine, this augmentation has not been confirmed. Using a contextual fear conditioning test in rats, an animal model of anxiety or fear, we examined the effect of subchronic lithium carbonate (in diet) in combination with systemic Mirtazapine on the expression of contextual conditioned fear. Mirtazapine (10mg/kg) reduced freezing one day after fear conditioning dose-dependently, whereas the anxiolytic-like effect of Mirtazapine (10mg/kg) diminished seven days after fear conditioning. When the interval between fear conditioning and testing was seven days, only the combination of subchronic 0.2% Li2CO3 but not 0.05% Li2CO3 with acute Mirtazapine (10mg/kg) reduced freezing significantly. These results indicate that subchronic 0.2% Li2CO3 treatment enhanced the anxiolytic-like effect of systemic Mirtazapine. This augmentation therapy might be useful for the treatment of anxiety disorders.
Takeshi Inoue - One of the best experts on this subject based on the ideXlab platform.
-
combined treatment with subchronic lithium and acute intracerebral Mirtazapine microinjection into the median raphe nucleus exerted an anxiolytic like effect synergistically
European Journal of Pharmacology, 2016Co-Authors: Yan An, Yuji Kitaichi, Shin Nakagawa, Takeshi Inoue, Chong Chen, Ce Wang, Ichiro KusumiAbstract:Abstract Although preclinical and clinical studies have established the efficacy of lithium augmentation of antidepressant drugs, the mechanism of action of lithium augmentation is not fully understood. Our previous study reported that subchronic lithium treatment enhanced the anxiolytic-like effect of systemic Mirtazapine. In the present study, we examined the effect of subchronic lithium in combination with acute local intracerebral injection of Mirtazapine on fear-related behaviors in a contextual fear conditioning test in rats to clarify the target brain region of lithium augmentation of Mirtazapine. After conditioning by footshock, diet (food pellets) containing Li 2 CO 3 at a concentration of 0.2% was administered for 7 days. Ten min before testing and 7 days after conditioning, Mirtazapine (3 μg/site) in a volume of 0.5 µl was acutely injected into the median raphe nucleus (MRN), hippocampus or amygdala. The combination of subchronic lithium and acute Mirtazapine microinjection into the MRN but not the hippocampus or the amygdala reduced fear expression synergistically. These results suggest that intra-MRN Mirtazapine treatment with subchronic lithium exerts the anxiolytic-like effect through the facilitation of the MRN-5HT pathway.
-
Subchronic lithium treatment increases the anxiolytic-like effect of Mirtazapine on the expression of contextual conditioned fear
European journal of pharmacology, 2014Co-Authors: Takeshi Inoue, Yuji Kitaichi, Shin Nakagawa, Ning Song, Chong Chen, Ce Wang, Ichiro KusumiAbstract:Lithium not only has a mood-stabilizing effect but also the augmentation effect of an antidepressant, the mechanism of which remains unclear. Although lithium may augment the effect of Mirtazapine, this augmentation has not been confirmed. Using a contextual fear conditioning test in rats, an animal model of anxiety or fear, we examined the effect of subchronic lithium carbonate (in diet) in combination with systemic Mirtazapine on the expression of contextual conditioned fear. Mirtazapine (10mg/kg) reduced freezing one day after fear conditioning dose-dependently, whereas the anxiolytic-like effect of Mirtazapine (10mg/kg) diminished seven days after fear conditioning. When the interval between fear conditioning and testing was seven days, only the combination of subchronic 0.2% Li2CO3 but not 0.05% Li2CO3 with acute Mirtazapine (10mg/kg) reduced freezing significantly. These results indicate that subchronic 0.2% Li2CO3 treatment enhanced the anxiolytic-like effect of systemic Mirtazapine. This augmentation therapy might be useful for the treatment of anxiety disorders.
-
anxiolytic like effect of Mirtazapine mediates its effect in the median raphe nucleus
European Journal of Pharmacology, 2013Co-Authors: Yan An, Yuji Kitaichi, Takeshi Izumi, Xiaobai Li, Shin Nakagawa, Takeshi Inoue, Ning Song, Chong Chen, Tsukasa KoyamaAbstract:Abstract Mirtazapine, a noradrenergic and specific serotonergic antidepressant (NaSSA), blocks the α2-adrenergic autoreceptors and heteroreceptors, which are responsible for controlling noradrenaline and 5-hydroxytryptamine (5-HT) release. Though preclinical and clinical studies have shown that Mirtazapine exerts an anxiolytic action, its precise brain target sites remain unclear. In the present study, we investigated the brain area(s) in which Mirtazapine exerts its anxiolytic-like effects on the expression of contextual conditioned freezing in rats. Mirtazapine (3 μg/site) was directly injected into three brain structures, the median raphe nucleus (MRN), hippocampus and amygdala. Freezing behavior tests were carried out 10 min after injections. Our results showed that the intra-MRN injection of Mirtazapine reduced freezing significantly, whereas injections into the hippocampus or the amygdala did not. In addition, the intra-MRN injection of Mirtazapine did not affect locomotor activity. These results suggest that the anxiolytic-like effect of Mirtazapine might be mediated by its action on the MRN.
Shin Nakagawa - One of the best experts on this subject based on the ideXlab platform.
-
combined treatment with subchronic lithium and acute intracerebral Mirtazapine microinjection into the median raphe nucleus exerted an anxiolytic like effect synergistically
European Journal of Pharmacology, 2016Co-Authors: Yan An, Yuji Kitaichi, Shin Nakagawa, Takeshi Inoue, Chong Chen, Ce Wang, Ichiro KusumiAbstract:Abstract Although preclinical and clinical studies have established the efficacy of lithium augmentation of antidepressant drugs, the mechanism of action of lithium augmentation is not fully understood. Our previous study reported that subchronic lithium treatment enhanced the anxiolytic-like effect of systemic Mirtazapine. In the present study, we examined the effect of subchronic lithium in combination with acute local intracerebral injection of Mirtazapine on fear-related behaviors in a contextual fear conditioning test in rats to clarify the target brain region of lithium augmentation of Mirtazapine. After conditioning by footshock, diet (food pellets) containing Li 2 CO 3 at a concentration of 0.2% was administered for 7 days. Ten min before testing and 7 days after conditioning, Mirtazapine (3 μg/site) in a volume of 0.5 µl was acutely injected into the median raphe nucleus (MRN), hippocampus or amygdala. The combination of subchronic lithium and acute Mirtazapine microinjection into the MRN but not the hippocampus or the amygdala reduced fear expression synergistically. These results suggest that intra-MRN Mirtazapine treatment with subchronic lithium exerts the anxiolytic-like effect through the facilitation of the MRN-5HT pathway.
-
Subchronic lithium treatment increases the anxiolytic-like effect of Mirtazapine on the expression of contextual conditioned fear
European journal of pharmacology, 2014Co-Authors: Takeshi Inoue, Yuji Kitaichi, Shin Nakagawa, Ning Song, Chong Chen, Ce Wang, Ichiro KusumiAbstract:Lithium not only has a mood-stabilizing effect but also the augmentation effect of an antidepressant, the mechanism of which remains unclear. Although lithium may augment the effect of Mirtazapine, this augmentation has not been confirmed. Using a contextual fear conditioning test in rats, an animal model of anxiety or fear, we examined the effect of subchronic lithium carbonate (in diet) in combination with systemic Mirtazapine on the expression of contextual conditioned fear. Mirtazapine (10mg/kg) reduced freezing one day after fear conditioning dose-dependently, whereas the anxiolytic-like effect of Mirtazapine (10mg/kg) diminished seven days after fear conditioning. When the interval between fear conditioning and testing was seven days, only the combination of subchronic 0.2% Li2CO3 but not 0.05% Li2CO3 with acute Mirtazapine (10mg/kg) reduced freezing significantly. These results indicate that subchronic 0.2% Li2CO3 treatment enhanced the anxiolytic-like effect of systemic Mirtazapine. This augmentation therapy might be useful for the treatment of anxiety disorders.
-
anxiolytic like effect of Mirtazapine mediates its effect in the median raphe nucleus
European Journal of Pharmacology, 2013Co-Authors: Yan An, Yuji Kitaichi, Takeshi Izumi, Xiaobai Li, Shin Nakagawa, Takeshi Inoue, Ning Song, Chong Chen, Tsukasa KoyamaAbstract:Abstract Mirtazapine, a noradrenergic and specific serotonergic antidepressant (NaSSA), blocks the α2-adrenergic autoreceptors and heteroreceptors, which are responsible for controlling noradrenaline and 5-hydroxytryptamine (5-HT) release. Though preclinical and clinical studies have shown that Mirtazapine exerts an anxiolytic action, its precise brain target sites remain unclear. In the present study, we investigated the brain area(s) in which Mirtazapine exerts its anxiolytic-like effects on the expression of contextual conditioned freezing in rats. Mirtazapine (3 μg/site) was directly injected into three brain structures, the median raphe nucleus (MRN), hippocampus and amygdala. Freezing behavior tests were carried out 10 min after injections. Our results showed that the intra-MRN injection of Mirtazapine reduced freezing significantly, whereas injections into the hippocampus or the amygdala did not. In addition, the intra-MRN injection of Mirtazapine did not affect locomotor activity. These results suggest that the anxiolytic-like effect of Mirtazapine might be mediated by its action on the MRN.
Yuji Kitaichi - One of the best experts on this subject based on the ideXlab platform.
-
combined treatment with subchronic lithium and acute intracerebral Mirtazapine microinjection into the median raphe nucleus exerted an anxiolytic like effect synergistically
European Journal of Pharmacology, 2016Co-Authors: Yan An, Yuji Kitaichi, Shin Nakagawa, Takeshi Inoue, Chong Chen, Ce Wang, Ichiro KusumiAbstract:Abstract Although preclinical and clinical studies have established the efficacy of lithium augmentation of antidepressant drugs, the mechanism of action of lithium augmentation is not fully understood. Our previous study reported that subchronic lithium treatment enhanced the anxiolytic-like effect of systemic Mirtazapine. In the present study, we examined the effect of subchronic lithium in combination with acute local intracerebral injection of Mirtazapine on fear-related behaviors in a contextual fear conditioning test in rats to clarify the target brain region of lithium augmentation of Mirtazapine. After conditioning by footshock, diet (food pellets) containing Li 2 CO 3 at a concentration of 0.2% was administered for 7 days. Ten min before testing and 7 days after conditioning, Mirtazapine (3 μg/site) in a volume of 0.5 µl was acutely injected into the median raphe nucleus (MRN), hippocampus or amygdala. The combination of subchronic lithium and acute Mirtazapine microinjection into the MRN but not the hippocampus or the amygdala reduced fear expression synergistically. These results suggest that intra-MRN Mirtazapine treatment with subchronic lithium exerts the anxiolytic-like effect through the facilitation of the MRN-5HT pathway.
-
Subchronic lithium treatment increases the anxiolytic-like effect of Mirtazapine on the expression of contextual conditioned fear
European journal of pharmacology, 2014Co-Authors: Takeshi Inoue, Yuji Kitaichi, Shin Nakagawa, Ning Song, Chong Chen, Ce Wang, Ichiro KusumiAbstract:Lithium not only has a mood-stabilizing effect but also the augmentation effect of an antidepressant, the mechanism of which remains unclear. Although lithium may augment the effect of Mirtazapine, this augmentation has not been confirmed. Using a contextual fear conditioning test in rats, an animal model of anxiety or fear, we examined the effect of subchronic lithium carbonate (in diet) in combination with systemic Mirtazapine on the expression of contextual conditioned fear. Mirtazapine (10mg/kg) reduced freezing one day after fear conditioning dose-dependently, whereas the anxiolytic-like effect of Mirtazapine (10mg/kg) diminished seven days after fear conditioning. When the interval between fear conditioning and testing was seven days, only the combination of subchronic 0.2% Li2CO3 but not 0.05% Li2CO3 with acute Mirtazapine (10mg/kg) reduced freezing significantly. These results indicate that subchronic 0.2% Li2CO3 treatment enhanced the anxiolytic-like effect of systemic Mirtazapine. This augmentation therapy might be useful for the treatment of anxiety disorders.
-
anxiolytic like effect of Mirtazapine mediates its effect in the median raphe nucleus
European Journal of Pharmacology, 2013Co-Authors: Yan An, Yuji Kitaichi, Takeshi Izumi, Xiaobai Li, Shin Nakagawa, Takeshi Inoue, Ning Song, Chong Chen, Tsukasa KoyamaAbstract:Abstract Mirtazapine, a noradrenergic and specific serotonergic antidepressant (NaSSA), blocks the α2-adrenergic autoreceptors and heteroreceptors, which are responsible for controlling noradrenaline and 5-hydroxytryptamine (5-HT) release. Though preclinical and clinical studies have shown that Mirtazapine exerts an anxiolytic action, its precise brain target sites remain unclear. In the present study, we investigated the brain area(s) in which Mirtazapine exerts its anxiolytic-like effects on the expression of contextual conditioned freezing in rats. Mirtazapine (3 μg/site) was directly injected into three brain structures, the median raphe nucleus (MRN), hippocampus and amygdala. Freezing behavior tests were carried out 10 min after injections. Our results showed that the intra-MRN injection of Mirtazapine reduced freezing significantly, whereas injections into the hippocampus or the amygdala did not. In addition, the intra-MRN injection of Mirtazapine did not affect locomotor activity. These results suggest that the anxiolytic-like effect of Mirtazapine might be mediated by its action on the MRN.
Chong Chen - One of the best experts on this subject based on the ideXlab platform.
-
combined treatment with subchronic lithium and acute intracerebral Mirtazapine microinjection into the median raphe nucleus exerted an anxiolytic like effect synergistically
European Journal of Pharmacology, 2016Co-Authors: Yan An, Yuji Kitaichi, Shin Nakagawa, Takeshi Inoue, Chong Chen, Ce Wang, Ichiro KusumiAbstract:Abstract Although preclinical and clinical studies have established the efficacy of lithium augmentation of antidepressant drugs, the mechanism of action of lithium augmentation is not fully understood. Our previous study reported that subchronic lithium treatment enhanced the anxiolytic-like effect of systemic Mirtazapine. In the present study, we examined the effect of subchronic lithium in combination with acute local intracerebral injection of Mirtazapine on fear-related behaviors in a contextual fear conditioning test in rats to clarify the target brain region of lithium augmentation of Mirtazapine. After conditioning by footshock, diet (food pellets) containing Li 2 CO 3 at a concentration of 0.2% was administered for 7 days. Ten min before testing and 7 days after conditioning, Mirtazapine (3 μg/site) in a volume of 0.5 µl was acutely injected into the median raphe nucleus (MRN), hippocampus or amygdala. The combination of subchronic lithium and acute Mirtazapine microinjection into the MRN but not the hippocampus or the amygdala reduced fear expression synergistically. These results suggest that intra-MRN Mirtazapine treatment with subchronic lithium exerts the anxiolytic-like effect through the facilitation of the MRN-5HT pathway.
-
Subchronic lithium treatment increases the anxiolytic-like effect of Mirtazapine on the expression of contextual conditioned fear
European journal of pharmacology, 2014Co-Authors: Takeshi Inoue, Yuji Kitaichi, Shin Nakagawa, Ning Song, Chong Chen, Ce Wang, Ichiro KusumiAbstract:Lithium not only has a mood-stabilizing effect but also the augmentation effect of an antidepressant, the mechanism of which remains unclear. Although lithium may augment the effect of Mirtazapine, this augmentation has not been confirmed. Using a contextual fear conditioning test in rats, an animal model of anxiety or fear, we examined the effect of subchronic lithium carbonate (in diet) in combination with systemic Mirtazapine on the expression of contextual conditioned fear. Mirtazapine (10mg/kg) reduced freezing one day after fear conditioning dose-dependently, whereas the anxiolytic-like effect of Mirtazapine (10mg/kg) diminished seven days after fear conditioning. When the interval between fear conditioning and testing was seven days, only the combination of subchronic 0.2% Li2CO3 but not 0.05% Li2CO3 with acute Mirtazapine (10mg/kg) reduced freezing significantly. These results indicate that subchronic 0.2% Li2CO3 treatment enhanced the anxiolytic-like effect of systemic Mirtazapine. This augmentation therapy might be useful for the treatment of anxiety disorders.
-
anxiolytic like effect of Mirtazapine mediates its effect in the median raphe nucleus
European Journal of Pharmacology, 2013Co-Authors: Yan An, Yuji Kitaichi, Takeshi Izumi, Xiaobai Li, Shin Nakagawa, Takeshi Inoue, Ning Song, Chong Chen, Tsukasa KoyamaAbstract:Abstract Mirtazapine, a noradrenergic and specific serotonergic antidepressant (NaSSA), blocks the α2-adrenergic autoreceptors and heteroreceptors, which are responsible for controlling noradrenaline and 5-hydroxytryptamine (5-HT) release. Though preclinical and clinical studies have shown that Mirtazapine exerts an anxiolytic action, its precise brain target sites remain unclear. In the present study, we investigated the brain area(s) in which Mirtazapine exerts its anxiolytic-like effects on the expression of contextual conditioned freezing in rats. Mirtazapine (3 μg/site) was directly injected into three brain structures, the median raphe nucleus (MRN), hippocampus and amygdala. Freezing behavior tests were carried out 10 min after injections. Our results showed that the intra-MRN injection of Mirtazapine reduced freezing significantly, whereas injections into the hippocampus or the amygdala did not. In addition, the intra-MRN injection of Mirtazapine did not affect locomotor activity. These results suggest that the anxiolytic-like effect of Mirtazapine might be mediated by its action on the MRN.
